Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 16/20 | 0.73 |
| ▸ | CSNK2A1 | P68400 | 16/20 | 0.73 |
| ▸ | CSNK2A2 | P19784 | 14/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.73 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.50 |
| ▸ | BUB1 | O43683 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263638 | 0.92 | CSNK2B (0.74) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL261530 | 0.85 | CSNK2B (1.00) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL262461 | 0.85 | CSNK2B (0.70) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL262572 | 0.83 | CSNK2B (0.71) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL261139 | 0.82 | CSNK2B (1.00) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL262516 | 0.81 | CSNK2B (0.69) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL262143 | 0.76 | ABCG2 (0.76) | CSNK2BCSNK2A1CSNK2A2ABCG2 | |
| SCHEMBL263321 | 0.75 | CSNK2B (0.80) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL261265 | 0.74 | CSNK2A1 (1.00) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 | |
| SCHEMBL261280 | 0.74 | CSNK2B (1.00) | CSNK2BCSNK2A1CSNK2A2ABCG2CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133913-B2 | Substituted indeno [1,2-b]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids | Heinrich-Heine Universitat Dusseldof (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20100056599-A1 | SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS | HEINRICH-HEINE UNIVERSITAT DUSSELDORF (DE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056599-A1 | SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS | CDK2, CSNK1A1, CDK1 | CSNK2B 11/4885CSNK2A1 4/4885CSNK2A2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.